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Abstract: Background Mitochondrial succinate accumulation has been suggested as key event for ischemia
reperfusion injury in mice. No specific data are however available on behavior of liver mitochondria dur-
ing ex situ machine perfusion in clinical transplant models. Methods We investigated mitochondrial
metabolism of isolated perfused rat livers before transplantation. Livers were exposed to warm and
cold ischemia to simulate donation after circulatory death (DCD) and organ transport. Subsequently,
livers were perfused with oxygenated Belzer-MPS for 1h, at hypothermic or normothermic conditions.
Various experiments were performed with supplemented succinate and/or mitochondrial inhibitors. The
perfusate, liver tissues, and isolated mitochondria were analyzed by mass-spectroscopy and fluorime-
try. Additionally, rat DCD livers were transplanted after 1h hypothermic or normothermic oxygenated
perfusion. In parallel, perfusate samples were analysed during HOPE-treatment of human DCD livers be-
fore transplantation. Findings Succinate exposure during rat liver perfusion triggered a dose-dependent
release of mitochondrial Flavin-Mononucleotide (FMN) and NADH in perfusates under normothermic
conditions. In contrast, perfusate FMN was 3-8 fold lower under hypothermic conditions, suggesting
less mitochondrial injury during cold re-oxygenation compared to normothermic conditions. HOPE-
treatment induced a mitochondrial reprogramming with uploading of the nucleotide pool and effective
succinate metabolism. This resulted in a clear superiority after liver transplantation compared to nor-
mothermic perfusion. Finally, the degree of mitochondrial injury during HOPE of human DCD livers,
quantified by perfusate FMN and NADH, was predictive for liver function. Interpretation Mitochondrial
injury determines outcome of transplanted rodent and human livers. Hypothermic oxygenated perfu-
sion improves mitochondrial function, and allows viability assessment of liver grafts before implantation.
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A B S T R A C T
Background:Mitochondrial succinate accumulation has been suggested as key event for ischemia reperfusion
injury in mice. No specific data are however available on behavior of liver mitochondria during ex situ
machine perfusion in clinical transplant models.
Methods: We investigated mitochondrial metabolism of isolated perfused rat livers before transplantation.
Livers were exposed to warm and cold ischemia to simulate donation after circulatory death (DCD) and organ
transport. Subsequently, livers were perfused with oxygenated Belzer-MPS for 1h, at hypothermic or normo-
thermic conditions. Various experiments were performed with supplemented succinate and/or mitochon-
drial inhibitors. The perfusate, liver tissues, and isolated mitochondria were analyzed by mass-spectroscopy
and fluorimetry. Additionally, rat DCD livers were transplanted after 1h hypothermic or normothermic oxy-
genated perfusion. In parallel, perfusate samples were analysed during HOPE-treatment of human DCD livers
before transplantation.
Findings: Succinate exposure during rat liver perfusion triggered a dose-dependent release of mitochondrial
Flavin-Mononucleotide (FMN) and NADH in perfusates under normothermic conditions. In contrast, perfus-
ate FMN was 3-8 fold lower under hypothermic conditions, suggesting less mitochondrial injury during cold
re-oxygenation compared to normothermic conditions. HOPE-treatment induced a mitochondrial reprog-
ramming with uploading of the nucleotide pool and effective succinate metabolism. This resulted in a clear
superiority after liver transplantation compared to normothermic perfusion. Finally, the degree of mitochon-
drial injury during HOPE of human DCD livers, quantified by perfusate FMN and NADH, was predictive for
liver function.
Interpretation: Mitochondrial injury determines outcome of transplanted rodent and human livers. Hypothermic
oxygenated perfusion improves mitochondrial function, and allows viability assessment of liver grafts before
implantation.
Funding: detailed information can be found in Acknowledgments.
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Current discoveries in the field of hepatic ischemia-reperfusion (I/
R) point to mitochondrial-derived oxidative stress as key mechanism
of tissue damage [13]. Optimization strategies for the treatment of
ischemic organs may, therefore, depend on effective protection from
mitochondrial injury. Ex situ perfusion of organs for transplantation
is a new and promising strategy to modify and improve cellular con-
ditions before implantation. Two main perfusion methods for livers
and kidneys have been developed and are currently under discussion
in clinical practice [4]. The first approach aims to simulate the in vivo
conditions of organ perfusion, at normothermic temperatures with
blood and nutrients at physiological perfusion pressure and flow [5].
In contrast, an alternative technique involves hypothermic organ
perfusion (412°C), with a blood-free preservation solution at non-
physiologic perfusion pressure and flows [6]. The effect of both perfu-
sion techniques on mitochondrial recovery of ischemic livers is
currently unknown.
Here, we unravel the role of the respiratory electron chain during
ex situ perfusion of ischemic livers under cold and warm conditions.
We used a standardized ex situ rat liver perfusion model with syn-
chronous fluorometric assessment of newly discovered markers of
mitochondrial injury. We performed a metabolic analysis of liver tis-
sues, intact mitochondria and acellular perfusate to assess mitochon-
drial function.
Collectively, our data suggest that, unlike normothermic oxygen-
ated perfusion, hypothermic oxygenated perfusion is protective
against liver ischemia-reperfusion injury. This phenomenon is trig-
gered by a unique response of mitochondria to ischemia-reperfusion
under hypothermic conditions. We have translated our findings in
the human setting of liver transplantation, and developed a tech-
nique to monitor liver function by a combination of two metabolic
markers, both detectable during cold perfusion and enabling us to
evaluate the quality of donor livers and predict graft implantation
success already before transplantation.
Methods
I. Rat liver experiments
Animals
Male Brown Norway rats (250320 g) were used for all rat experi-
ments. Animals were maintained on laboratory diet and water
according to the Swiss Animal Health Care law. All experiments were
approved by the cantonal veterinary office Zurich (01/2012, 218/
2014). Anesthesia during liver procurement was maintained with iso-
flurane. Additional rat liver transplant experiments were authorized
by the Italian animal authority (Direzione generale della sanita ani-
male e dei farmaci veterinary) according to the protocol No 90/2020-
PR. Experiments were done in the laboratory linked to the animal
facility of the University Hospital Zurich and the Centro di Stabula-
zione degli animali da laboratorio (Ce.S.A.L.), Firenze.
Study design and experimental groups
All experiments were carried out with a donation after circulatory
death (DCD) animal model (30 min in situ warm ischemia) with sub-
sequent cold ischemia for 4 h. Ex situ reperfusion was performed for
1h either normothermically (normothermic oxygenated perfusion,
NT) at 37°C with Belzer MPS, or hypothermically (hypothermic oxy-
genated perfusion, HOPE) at 10°C with Belzer MPS. We added succi-
nate every 10 min by repeated bolus injection, in the presence or
absence of mitochondrial inhibitors during perfusion. We chose the
following experimental groups with random assignment for NT or
HOPE:
1. Belzer MPS without succinate
2. Belzer MPS + 2.5 mM succinate
3. Belzer MPS + 25 mM succinate
4. Belzer MPS + 250 mM succinate
Experiment 2 was repeated with either additional malonate
(20 mM), rotenone (0.035 mM), or cyanide (20 mM) in the perfusate.
Additional experiments were performed with adding ethanol
(200 mM) in the presence or absence of 4-methylpyrazol (100 mM)
during HOPE.
Additional experiments were also performed for NT with perfu-
sion with diluted blood, and with NT performed after HOPE. In some
experiments we performed also an intermittent perfusion stop
(ischemia) for 10 min with subsequent reperfusion.
In a next step, we assessed metabolic and mitochondrial function
in DCD rat livers before and after HOPE, without adding succinate
during perfusion.
Research in Context
Evidence before this study
Recent work has highlighted that succinate accumulation dur-
ing ischemia is an inevitable part of every organ procurement
and transplantation, causing relevant injury during ischemia-
reperfusion by electron overflow at mitochondrial complex I.
While this scenario is well defined for re-oxygenation under
normothermic conditions, little is known on mitochondrial
behavior during cold oxygenation. Here we uncover in a trans-
lational project a novel mechanism, by which oxygenated
reperfusion in the cold leads to significantly less mitochondrial
injury in livers, despite succinate provocation, when compared
to normothermic conditions.
Added value of this study
First, we show in rodent livers, that the release of mitochon-
drial flavin mononucleotide (FMN) during reoxygenation after
ischemia under normothermic conditions depends on mito-
chondrial succinate. Secondly, reperfusion (reoxygenation)
under cold conditions (HOPE) induces also mitochondrial FMN
release, dependent on succinate levels, but to a significant less
degree. Third, HOPE-treatment (cold oxygenation) induces a
metabolic switch in mitochondria through an improved enzy-
matic activity of complex I, II and IV. Such findings correlate
with a decrease of lactate, succinate, and purine derivates in
liver tissues after HOPE, and are further paralleled by an
increase of mitochondrial ATP and a reduced NADH/NAD ratio.
Fourth, HOPE treated livers disclose consecutively less oxida-
tive injury and less downstream inflammation during subse-
quent transplantation. Finally, the extent of mitochondrial FMN
and NADH release during HOPE in human livers, and the linked
nucleotide breakdown as a consequence of mitochondrial func-
tion, is a signature for liver graft injury, and serves as a predic-
tor for human liver graft function before implantation.
Implications of the available evidence
We report a novel mechanism of preventing liver ischemia
reperfusion injury, which allows simultaneously monitoring of
liver graft injury while restoring mitochondrial function. We
expect a high clinical impact due to the urgent clinical need for
safe utilization of injured livers.
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The following groups were investigated:
Baseline: fresh resected liver without warm ischemia and minimal
(0.5 h) cold ischemia
DCD + CS: 30 min in situwarm ischemia + 4 h cold storage
DCD + CS + 1 h HOPE: 30 min in situ warm ischemia + 4 h cold
storage + 1 h HOPE
All experimental groups consisted of at least 6 experiments per
groups.
Liver procurement and cold storage
Following midline incision, cardiac arrest was induced by
opening of the diaphragm without previous heparinization of
donor animals. After 30 min of in situ warm ischemia, livers were
flushed in situ with 10 ml cold heparinized Institute George Lopez
(IGL)-1 solution via the portal vein. Livers were then excised
(weight 9.8 § 0.6 g) and placed in precooled IGL-1 solution at 4°
C. Afterwards, livers tissues were either exposed to 4h cold stor-
age alone (for tissue analysis and mitochondrial isolation) or to
4 h cold storage followed by ex situ perfusion under different
conditions (see above). For machine perfusion, all livers received
a stent in the portal vein.
Hypothermic oxygenated perfusion (HOPE)
Livers to be perfused at 10°C were connected to the precooled
perfusion device after initial cold storage. Machine perfusion was
maintained for 1 h under computerized pressure control (3 mmHg),
resulting in flow rates between 1 and 2 ml/minutes. Active oxygen-
ation was provided by a hollow fiber oxygenator (Hugo Sachs Elec-
tronic), delivering a perfusate pO2 of 6080 kPa. We used 100 ml
recirculating UW gluconate solution (Belzer MPS) as perfusate. The
perfusion box and perfusate were both maintained at 10°C by an
open bath thermostat (Huber, Germany).
Normothermic oxygenated perfusion
Livers to be perfused at 37°C were connected to the prewarmed
perfusion device after initial cold storage. Machine perfusion was
maintained for 1 h under computerized pressure control (12 mm
Hg), resulting in flow rates between 1518 ml/min. Active oxygen-
ation was provided as in hypothermic perfusion experiments. We
used 100 ml recirculating UW gluconate solution (Belzer MPS) or
diluted blood as perfusate. The perfusion box and perfusate
were both maintained at 37°C by an open bath thermostat (Huber,
Germany).
Additional normothermic perfusion experiments were performed
using diluted heparinized blood (hematocrit 1416) instead of Belzer
MPS. The perfusate was substituted with nutrients according to ear-
lier reports [7].
Transplant experiments
We performed orthotopic liver transplantation in controls (non-
ischemic livers, baseline), cold storage DCD livers (30 min in situ
warm ischemia + 4 h cold storage), in HOPE treated DCD livers
(30 min in situ warm ischemia + 4 h cold storage + 1 h HOPE), and in
normothermically perfused DCD livers (30 min in situ warm
ischemia + 4 h cold storage + 1 h normothermic perfusion with
diluted blood). Liver transplantation was performed as previously
reported [7]. Liver tissue and blood samples were taken after 24 h.
Endpoints
1. Quantification of FMN
Real time release of flavin mononucleotide (FMN) in the perfusate
was determined by fluorescence spectroscopy. A light probe was con-
nected to a halogen light source to emit monochrome light at a wave-
length of 450 nm on the recirculating perfusate (Fig. 1A-B). A
spectrometric receiver probe with sufficiently high resolution (e.g.
4.6 nm) was used to quantify the proportion of emitted fluorescent
light by the FMN molecules. The fluorescence emission maximum of
FMN was measured between 500600 nm (Avaspec HS2048XL-EVO,
Avantes).
Flavin mononucleotide (FMN) was also determined by a lab-
based fluorescence assessment from perfusate samples. All sam-
ples containing blood cells were primarily centrifugated before
assessment. Additionally, we confirmed these measurements by
targeted liquid chromatography-mass spectroscopy (LC-MS).
Results from different types of measurements (fluorescence spec-
troscopy and LC-MS were correlated for each sample. Fluores-
cence measurements were calibrated with standards to confirm
increasing concentrations correlate with increasing positivity at
the respective wavelength.
2. Quantification of NADH
Mitochondrial respiration rate during cold machine perfusion was
measured by the amount of oxidized NADH (NAD+), determined
spectroscopically and also by fluorescence in perfusates samples
(excitation wavelength 360 nm, emission peak 460 nm). In addition,
perfusate NAD+ and NADH values were determined by targeted Liq-
uid Chromatography-mass spectroscopy (LC-MS). Results from differ-
ent types of measurements (fluorescence spectroscopy and LC-MS
were correlated. The spectroscope was calibrated with NADH stand-
ards to confirm increasing concentrations correlate with increasing
positivity at the respective wavelength.
3. Quantification of 8-OHdG and HMGB-1 (in Perfusate)
Oxidative damage of DNA was detected in plasma by 8-hydroxy-
2-deoxy Guanosine (8-OHdG) ELISA (Abnova; KA0444) and nuclear
injury was measured by release of high mobility group box protein 
1 (HMGB-1; IBL International GmbH; ST51011).
4. Histology and Immunohistochemistry
The following staining procedures were performed after 1h perfu-
sion in each experimental group: 8-OHdG (AA1005.1), Haematoxy-
lin-Eosin (H&E) - staining for necrosis, Toll-Like-Receptor-4
staining (TLR-4; LS-B2070, RRID:AB_1277478), CD 68  staining
(macrosialin; MCA341R, RRID:AB_2291300), ICAM (Santa Cruz, RRID:
AB_631159). Histological assessments were determined by manual
counting in 20 random visual fields (2.5x or 10x). All histological
analyses were performed in a blinded fashion with respect to the
experimental groups.
5. Metabolite extraction and profiling by targeted liquid chroma-
tography-mass spectrometry (LC-MS/MS)
About 30 mg of N2 shock frozen liver tissues and 30 ml of perfus-
ate samples (per experimental group and run) were used for metabo-
lite profiling. Homogenization for liver tissues was performed with a
FastPrep (60 s, 4 m x s1) in a buffer containing 1.5 ml methanol and
0.1% ammonium acetate. The protein pellet gained after brief centri-
fugation was used in a bicinchoninic acid (BSA) based protein assay
for normalization among samples. An internal standard (IS) mixture,
containing chloramphenicol and C13-labeled L-glutamine, L-arginine,
L-proline, L-valine, and uracil was added to each supernatant (10 mM
final concentration).
For metabolite extraction in perfusates, proteins were precipi-
tated by the addition of two volumes of acetonitrile, vortexing for
5 min and centrifugation (16.000) at 4C° for 10 min. Again, the
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protein pellets were used for normalization and an (IS) was added, as
above. Metabolites in the supernatants were extracted with methyl
tert-butyl ether (MTBE), methanol, and water [8].
Subsequent separation of the metabolites was performed on an LC
instrument (1290 series UHPLC; Agilent, Santa Clara, CA), online cou-
pled to a triple quadrupole hybrid ion trap mass spectrometer QTrap
6500 (Sciex, Foster City, CA), based on multiple reaction monitoring
(MRM) method, as reported previously [9]. Three transitions per
selected metabolite were measured.
Relative quantification was performed using MultiQuantTM soft-
ware v.2.1.1 (Sciex, Foster City, CA). Peak integrations were reviewed
manually and peak intensities were normalized, first against the
internal standards, and subsequently against protein abundances
obtained from the BCA assay. The first transition of each metabolite
was used for relative quantification between samples.
Nicotine adenine dinucleotide (NAD), succinic acid, inosine,
inosine monophosphate (IMP), adenosine monophosphate (AMP),
adenosine diphosphate (ADP), adenosine trisphosphate (ATP), hypo-
xanthine, xanthine, fumaric acid, lactate, uric acid, and flavin mono-
nucleotide (FMN) were determined by targeted LC-MS/MS.
6. Mitochondrial analysis, complex I, II, IV activity
Liver mitochondria membranes were isolated from fresh rat liver
samples, e.g. DCD livers before and after HOPE or NT, immediately
frozen in liquid nitrogen at -80°C. Healthy control livers, without
exposure to ischemia, served as baseline. We performed, first, a met-
abolic analysis of isolated mitochondria, to determine purine, pyrimi-
dine nucleotides and FMN in relation to mitochondrial succinate.
Next, we investigated mitochondrial function of complex I, II, and IV
as explained in detail in [24]. Complex I NADH-dependent activities
were measured spectrophotometrically using Molecular Device plate
reader (Varian Cary 4000 or plate-reader Molecular Devices) at 25°C
as a decrease in absorption at 340 nm with 120 mM NADH in
standard assay medium (0.25 M sucrose, 50 mM Tris-HCl pH 8.5,
0.2 mM EDTA, 15 mg/ml alamethicin, 2 mM MgCl2) and containing
1520 mg protein/ml of membranes. Permeabilisation with alame-
thicin stimulates any NADH-dependent activities around 30%, indi-
cating that our preparation contains 30% of still intact mitochondria
membranes even after freezing/thawing cycle. In order to estimate
relative content of Complex I, measurements of NADH: HAR oxidore-
ductase were carried out in the standard assay medium with 1 mM
HAR. Rotenone sensitive (>95%) NADH:decylubiquionone reductase
activity of Complex I alone was measured in standard assay medium
supplemented with cyanide (2 mM) and 31 mM decylubiquinone
(DBQ). Ferrocytochrome c oxidase activity of Complex IV was mea-
sured in assay medium (125 mM KCl, 14 mM NaCl, 20 mM HEPES,
0.2 mM EGTA pH 7.2) with 0.025% n-dodecyl b-d-maltoside (DDM)
and 55mM of reduced ferrocytochrome c [10]. The enzymatic activity
was 100% sensitive to 0.5 mM cyanide. Succinate dehydrogenase
activity was determined spectrophotometrically with Q1 (15 mM) as
electron acceptor in standard medium supplemented with 20 mM
succinate and 1 mM cyanide. All obtained mitochondrial preparations
catalyze succinate oxidation (not shown) with a pronounced lag-
phase with initial rate is 3060% of the final linear steady-state
rate (not shown). Prior to activity measurements membranes
were incubated with malonate to replace OAA from the binding site
(30 min £ 30C).
II. Human liver perfusion
Perfusate samples were obtained during hypothermic oxygenated
perfusion (HOPE) of human liver grafts donated after circulatory
death (DCD). Following standard cold storage with IGL-1, livers
underwent a pressure controlled hypothermic perfusion at 10 ° with
highly oxygenated perfusate (PO2 6080 kPa) for 12 h. Perfusion
was performed at 10°C using Belzer MPS (Bridge to Life) as perfusate
and the Liver Assist device (Organ Assist). During perfusion, multiple
Fig. 1. Perfusion circuit and online fluorescence of FMN
The perfusion circuit used for all rat liver perfusions included a temperature control device, flow and pressure sensors, the perfusion chamber, where the liver was placed with
another temperature sensor, the sampling port, an injection port for the application of succinate or mitochondrial blockers, and a flow cell at the outflow of the liver to quantify the
fluorescence (a). Detection of the emitted light was quantified between 500600 nm, while excitation was performed at a wavelength of 450 nm. Normo- or hypothermic oxygen-
ated perfusion was performed with a computer adjusted pressure-controlled system to automatically limit perfusion pressure at 12 mm Hg (normothermic) or at 3 mm Hg (hypo-
thermic), and to allow the liver to autoregulate the flow, which becomes subsequently detected by a flow sensor.
Real time response with an increasing fluorescence is demonstrated in accordance with succinate supplementation during normothermic perfusion, while under hypothermic
oxygenated conditions, much lower perfusate fluorescence FMN release was detected despite succinate trigger (b).
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perfusate samples were obtained and analyzed by fluorimetry (per-
fusate 1:4 diluted) and LC-MS. The results were correlated to clinical
parameters after liver transplantation, including graft survival. HOPE
perfusates were also assessed for nicotine adenine dinucleotide
(NAD), succinic acid, inosine, inosine monophosphate (IMP), hypo-
xanthine, xanthine, uric acid, N-acetyl-L-glutamic acid and flavin
mononucleotide (FMN) through LC-MS.
Quantification and Statistical analysis
All activities were measured in duplicates or quadruplicates at 25°
C. All activities are shown inmmol substrate/min/mg protein. All data
are presented using the median and interquartile range (IQR) for con-
tinuous variables. The non-parametric Mann-Whitney U-test was
used to determine whether significant differences existed between 2
groups. A p value of <0.05 was deemed statistically significant. Pear-
son’s parametric correlation was used to assess the relationship
between to metric variables.
Receiver-operating characteristic (ROC) curves were used to
determine the threshold of highest sensitivity and specificity in
human perfusate FMN samples for liver graft loss.
All data were analyzed using IBM SPSS v.24.0 (Armonk, NY:
IBM Corp.) and GraphPad Prism, version 8.0 (San Diego, CA, USA).
Quality control and ethical approval
Completeness, plausibility, and validity of the data were indepen-
dently verified (by A.Sc., X.M., A.St., M.M., P.M., A.G., D.M. and P.D.).
The study approval from the cantonal ethics commission was
obtained prior to study initiation (ZH-Nr. 2015-0200). Animal experi-
ments were approved by the cantonal veterinary office Zurich (01/
2012, 218/2014) and protocol No 90/2020-PR.
Role of the Funding source
We confirm that all funders played no role in study design, data
collection, data analysis, interpretation, or writing of the report.
Results
Mitochondrial response during normothermic and hypothermic liver
reperfusion
Oxygenation of ischemic tissue results in oxidative stress, gener-
ated by an electron leak at mitochondrial complex I [1,11]. The pri-
mary driver of such mitochondrial-derived reactive oxygen species
(ROS) is an ischemic accumulation of the tricarboxylic acid (TCA)
cycle metabolite succinate [3,1113]. Data obtained from ischemic
brain mitochondria have further suggested, that the flavin mononu-
cleotide (FMN) site of complex I is responsible for the production of
ROS via reverse electron transfer (RET), and that accumulation of suc-
cinate triggers release of FMN from mitochondrial complex I
[2,14,15].
We intended, therefore, to investigate, if mitochondrial FMN
release occurs also in livers during I/R, and how this phenomenon
depends on temperature. We used an isolated perfused rat liver
model, with circulating acellular buffer (Belzer Machine Perfusion
Solution (MPS)), the currently most used machine perfusate for all
abdominal organs [16,17]. We chose a clinical related model with liv-
ers injured by a combination of warm in situ ischemia, simulating
donation after circulatory death (DCD), and subsequent cold storage,
simulating conventional organ transport before transplantation.
Furthermore, we added succinate to the circulating perfusate and
analyzed succinate uptake in liver mitochondria at different tempera-
tures, as well as related mitochondrial injury.
For this purpose, we applied a continuous real-time fluorimetry of
the perfusate, using an excitation wavelength at 360 nm (NADH) and
450 nm (FMN), and emission spectra between 400 and 600 nm
(Fig. 1, Supplemental Figure 1d). High levels of perfusate oxygen (pO2
6080 kPa) compensated the lack of red blood cells [1820].
Normothermic reoxygenation of DCD livers causes mitochondrial injury
In a first step, we showed, that cumulative mitochondrial succi-
nate uptake from perfusate was not different between hypo- and
normothermic perfusion (Supplementary Fig. 1a). Due to limited cel-
lular membrane permeability for succinate, however, mitochondrial
succinate increase was approximately 200-fold less than added per-
fusate succinate (Supplementary Fig. 1b). Next, we demonstrated
that acellular perfusion of rodent DCD livers at 37°C, without includ-
ing mitochondrial substrates, resulted in a significant release of FMN
in the perfusate (Fig. 2a), detectable by both, fluorimetry and NMR
analysis (Rho = 0.8327) (Fig. 2b). Notably, perfusate FMN increased
further under normothermic perfusion with blood instead of Belzer
MPS (Fig. 2a). We observed also, that the presence of succinate in the
circulating perfusate at normothermic (37°C) conditions, triggered a
dose-dependent FMN increase (Fig. 2 c, d), similar as intermittent
exposure of livers to 10 min ischemia (Fig. 2c, Supplementary Fig. 1d).
Furthermore, perfusate FMN correlated well with perfusate NAD/
NADH and IMP (Fig. 2e, f), but not with the release of cytosolic
enzymes, e.g. AST and ALT (Fig. 2f), indicating the absence of cell rup-
ture. In addition, mitochondrial FMN and nucleotide content were
inversely related to perfusate values (Fig. 2h, Supplementary Fig. 1c,
e, f), pointing to mitochondrial origin of FMN release.
Next, high perfusate succinate concentrations under normother-
mic conditions induced oxidative stress, assessed by an increased
concentration of 8-OHdG and HMGB in the perfusate, and with
downstream activation of Kupffer cells, visualized by specific immu-
nostaining for 8-OHdG, and toll-like receptor-4 activation (TLR-4)
(Fig. 3ad).
Third, we showed that succinate in the presence of malonate, a
competitive inhibitor of the carboxylate binding site of complex II,
increased once more NADH and FMN release (Fig. 4a, c), in contrast
to inhibition of complex IV by cyanide or inhibition of complex I by
rotenone (Fig. 4c). Succinate plus malonate resulted in increased
purine salvage, detectable by high IMP simultaneously with low
hypoxanthine and xanthine (Fig. 4eh).
Hypothermic reoxygenation of DCD livers is less harmful
In another set of experiments, we investigated whether FMN
released from mitochondria occurred also during hypothermic oxy-
genated perfusion (HOPE) at 10°C. However, in contrast to the nor-
mothermic perfusion experiments above, we observed a 3 to 8-fold
lower FMN release with and without succinate exposure (Fig. 2g, 4d).
Consistently, the NADH content in the perfusate was significantly
less, compared to normothermic conditions, despite an excess of suc-
cinate during HOPE (Fig. 3b, 4b), and mitochondrial concentrations of
FMN remained high (Fig. 2h). In addition, downstream activation of
Kupffer and endothelial cells were not detectable during HOPE
(Fig. 3), indicating less overall inflammation. Of note, neither inhibi-
tion of complex I, II or complex IV resulted in increased FMN
(Fig. 4d). Increased mitochondrial injury was further visualized by
staining of released NDUFS-1, e.g. one of the core subunits of the N-
module of complex I, which accommodate FMN and the iron clusters
N1a, N3, N1b, N4, and N5. Cytosolic NDUFS-1 was detectable after
normothermic perfusion with succinate in contrast to hypothermic
perfusion (Fig. 2b).
Importantly, while succinate alone failed to provoke high release
of FMN under hypothermic oxygenated conditions, inhibition of com-
plex I and II together caused FMN release (Fig. 4d), as well as adding
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Fig. 2. a: Detection of mitochondrial FMN and metabolite release in perfusates: Release of FMN occurred at various perfusate conditions, including hypothermic or normothermic
acellular perfusion, and by normothermic perfusion with whole blood, which resulted in highest FMN release (n = 20) (a). Perfusate FMN, detected by fluorescence, was validated
by NMR analysis (Rho = 0.8327) (measured in all rodent samples n> 55) (b). Administration of succinate or intermittent ischemia/reperfusion triggered relevant FMN release during
normothermic perfusion. (n = 67 for all groups other than: 60 min normotherm alone: n = 19 and n = 4 in FMN calibration) (c). Release of FMN increased in accordance with the
amount of administered succinate (2.5 mM< 25 mM< 250 mM succinate; n = 67 for all groups) (d). Perfusate NADH quantification through spectroscopy demonstrated increasing
concentrations according to administered succinate (n = 15 for all groups other than: NT without succinate, n = 5) (e). Perfusate FMN concentrations correlated also well with NAD
(Rho = 0.9746) and IMP (Rho = 0.8633), in contrast to release of cytosolic liver enzymes (AST, ALT) (n = 50, human samples) (f). Neither succinate application or intermittent ische-
mia/reperfusion was found to trigger high FMN release during hypothermic oxygenated perfusion (n = 6 other than calibration group, n = 4 and end of 60 min hypotherm: n = 18)
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of NADH donors (ethanol). In contrast, adding ethanol in the presence
of methylpyrazol, e.g. inhibiting the NADH producing ethanol dehy-
drogenase, prevented FMN release (Fig. 4d). Such experiments sup-
port the hypothesis, that FMN release is mainly induced in the cold
by an increase of reduction state of complex I and increase of NADH/
NAD+ ratio [2,21].
In summary, under conditions of normothermic reperfusion in the
presence of high intra-mitochondrial succinate concentrations, com-
plex I-bound FMN dissociates due to over-reduction of the enzyme. A
reductive dissociation of FMNH2 would be followed by a rapid non-
enzymatic oxidation to FMN by oxygen with ROS formation [22]. As a
consequence, mitochondrial oxidative injury occurs under normo-
thermic reperfusion conditions, and is further aggravated by malo-
nate (Fig. 5a). In contrast, FMN release and oxidative stress decreases
significantly under hypothermic reperfusion conditions, despite suc-
cinate provoke and despite the presence of malonate (Fig. 5b). Of
note, the extent of mitochondrial FMN release during I/R is easily
detectable in the perfusate during oxygenated liver perfusion,
regardless of the perfusion temperature applied.
Metabolic reprogramming of ischemic rat liver mitochondria by HOPE
treatment
After demonstrating low mitochondrial injury during cold reoxy-
genation of rat DCD livers, we analyzed mitochondrial function in iso-
lated mitochondria after cold storage, and after applying HOPE
subsequently to cold storage. We found, first, a clear decrease in
both NADH: hexaammineruthenium (HAR) reductase and NADH:
decylubiquinone (DBQ) reductase activity of complex I in conven-
tional stored DCD livers (Fig. 6a; a). In contrast, HOPE treatment of
cold-stored DCD livers significantly improved the enzymatic activity
of complex I (Fig. 6a; a). Secondly, HOPE also increased the activity of
complex II and complex IV (Fig. 6a; bc). These results correlated
well with a significant decrease of lactate, succinate, and hypoxan-
thine levels in liver tissues by HOPE, as well as in an increase of liver
ATP (Fig. 6a), and a significant decrease of the NADH/NAD ratio.
We confirmed these results in additional experiments on a mito-
chondrial level, with application of high doses (250 mM) of perfusate
succinate during HOPE, followed by normothermic reperfusion.
HOPE treatment enabled mitochondria to completely fuel down suc-
cinate and restore nucleotides, while preventing FMN loss and down-
stream inflammation, in contrast to untreated livers (Fig. 6b).
We conclude, that HOPE treatment for one hour in rat DCD livers
is sufficient to induce mitochondrial reprogramming towards more
oxidized state and to upload the adenine nucleotide pool. This effect
is caused by the improved function of mitochondrial respiratory com-
plexes.
Liver transplant function improved after HOPE compared to
normothermic oxygenated perfusion
To further confirm our findings, we analyzed liver function, liver
tissue ATP and histology after transplantation of unperfused and per-
fused DCD rat livers (30 min warm in situ ischemia + 4 h cold storage),
e.g. after cold storage alone, after endischemic normothermic oxy-
genated perfusion with diluted blood for 1 h, and after endischemic
(g). Mitochondrial FMN concentrations were inversely correlated to perfusate FMN, with low intramitochondrial FMN after normothermic perfusion. In contrast, mitochondria were
significantly protected from FMN loss during hypothermic oxygenated perfusion despite succinate application (n = 612) (h) (Mann-Whitney U-test was used for statistical analy-
sis). Fig. 2b: Imaging of mitochondrial complex I injury: cytosolic staining of released NDUFS-1: With high liver injury, NDUFS-1, a subunit of complex I dissociates from complex 1
and is released into the cytosol. Liver tissues were stained for NDUFS-1 in different groups. Normothermic perfusion with 250 mM Succinate led to high injuries of the mitochondrial
complex I as shown by a high number of NDUFS-1 positive hepatocytes in the staining, when compared to hypothermic perfusion, where almost no NDUFS-1-positive cytosols were
seen.
Fig. 3. Downstream inflammation under conditions with maximal succinate administration in perfusates: Histological images of various cellular compounds in livers perfused
under normothermic or hypothermic conditions with exposure to perfusate succinate. Parenchymal and non-parenchymal liver cells were protected from oxidative injury and acti-
vation under hypothermic conditions. In contrast, reperfusion under normothermic conditions induced oxidative injury, toll like receptor- and Kupffer cell activation (n = 6 and 8,
and 2 HPF/experiment) (a). These findings were paralleled by higher perfusate NADH concentrations (n = 15, duplicates) (b), higher oxidated DNA (n = 6 and 8) (C), and higher
release of danger signals (HMGB-1) during normothermic perfusion, when compared to hypothermic conditions (n = 6) (d) (Mann-Whitney U-test was used for statistical analysis).
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perfusion increases perfusate NADH perfusion increases perfusate NADH 
Fig. 4. Assessment of mitochondrial function during normo- and hypothermic perfusion in the presence of mitochondrial inhibitors: Various mitochondrial inhibitors were admin-
istered during liver perfusion together with succinate. Inhibition of complex II by malonate triggered increase of perfusate NADH during normothermic (a) and during hypothermic
conditions (b). However, complex II inhibition caused only under normothermic conditions relevant FMN release (c), in contrast to hypothermic perfusion (HOPE) (d). During HOPE,
high FMN release occurred with a combination of complex I and complex II inhibitors, or by excess of NADH donors (d). Administration of increasing succinate, or administration of
a combination of succinate and malonate, led to increasing NAD in perfusates under normothermic conditions (e). Succinate plus malonate resulted also in increased purine salvage,
detectable by high IMP (f) simultaneously with low hypoxanthine and xanthine (n =810, single measurements or duplicates) (g, h) (Mann-Whitney U-test was used for statistical
analysis).
Fig. 5. Mechanism of reoxygenation under normo- and hypothermic conditions: Under conditions of normothermic reperfusion in the presence of increased intra-mitochondrial
succinate concentrations ①, complex I-bound FMN dissociates due to over-reduction of NADH dehydrogenase②. A reductive dissociation of FMNH2 would be followed by a rapid
oxidation to FMN by oxygen with ROS formation③ and significant mitochondrial dysfunction, leading to ATP breakdown ④. As a consequence, mitochondrial oxidative injury
occurs under normothermic reperfusion conditions, and is further aggravated by malonate (a). In contrast, FMN release and oxidative stress decreases significantly under hypother-
mic reperfusion conditions, despite succinate provoke and despite the presence of malonate (b).
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hypothermic oxygenated perfusion with Belzer MPS for 1 h. The
results showed in accordance to earlier reports [7], that normother-
mic perfusion improved ATP and decreased hepatocellular injury
compared to cold storage. HOPE treatment resulted however in fur-
ther upload of ATP and best protection compared to cold storage or
endischemic normothermic perfusion (Fig. 6c).
Flavin and NAD/NADH in liver perfusate serves as viability marker in
human liver transplantation
Based on previous experimental research, we have been using
cold oxygenated machine liver perfusion (HOPE) since 2012 in
human extended criteria donor livers before transplantation, to opti-
mize graft quality [16]. Currently, approximately 120 HOPE-treated
human livers have been implanted in Zurich, with an overall 5-year
graft survival, censored for tumor related recipient death, of more
than 90% [16]. Within a translational aspect of the present study we
analyzed the perfusate for FMN and metabolite release of fifty human
livers, treated by HOPE before implantation. Corresponding to the
experiments in rodent DCD livers above, we found an initial FMN
release within the first 1030 min of HOPE treatment in human liv-
ers (Fig. 7a), with significant differences comparing DCD and DBD
grafts (Fig. 7b). In addition, the quantity of perfusate FMN during
HOPE correlated well with graft function and clinical outcome after
graft implantation. For example, perfusate analysis of livers, which
developed irreversible graft injury, e.g. primary non-function (PNF)
or irreversible cholangiopathy, revealed extremely high FMN values
within the first 30 minutes of HOPE perfusion, which was therefore
predictive for graft loss (c-statistic 0.94, Fig. 7c). A comparison of
metabolites in perfusates of failed (n = 7) vs survived grafts (n = 43)
showed 8-fold higher FMN values and 6-fold higher NAD values in
grafts which were lost (Fig. 7df). All purine metabolites (IMP, ino-
sine, xanthine, hypoxanthine, uric acid) were also significantly differ-
ent.
We conclude, that the extent of nucleotide breakdown as a conse-
quence of mitochondrial dysfunction is a signature for graft injury,
and predictive for human liver graft function. FMN and NAD/NADH
release appear as novel perfusate markers for assessing mitochon-
drial metabolism and cumulative graft injury already during donor
liver machine perfusion.
Discussion
The results of this study point to a uniform mechanism of mito-
chondrial-based liver I/R injury. First, we show that succinate
accumulation and flavin mononucleotide (FMN) release from
Fig. 6. a: Mitochondrial complex IIV function without and with hypothermic oxygenated perfusion (HOPE): Hypothermic oxygenated perfusion (HOPE), applied in DCD livers after
cold ischemia, improved complex I, II and IV function (n = 1112)(a, b, c). Subsequently, this resulted in decreased NADH/NAD tissue ratios (d), while lactate and succinate were
metabolized (e, f), and liver ATP was uploaded (g) by purine salvage pathways (h). Fig. 6b: Mitochondrial reprogramming by hypothermic oxygenated perfusion (HOPE): Isolated
mitochondria were analyzed by metabolite extraction and targeted liquid chromatography mass spectroscopy in four experimental groups, e.g. in normothermic perfusion (NT) of
rat DCD livers, without or with high perfusate succinate (250 mM), and in HOPE treated rat DCD livers, with application of 250 mM succinate already in the HOPE perfusate, fol-
lowed by normothermic perfusion. Despite the presence of high intramitochondrial succinate load during HOPE treatment, mitochondria maintained functioning with preserved
FMN and NAD, metabolized succinate, and uploaded purine nucleotides, in contrast to untreated livers (n = 1012, except NADH: n = 6) (Mann-Whitney U-test was used for statisti-
cal analysis). Fig. 6c: DCD liver injury & ATP 24 h after liver transplantation: Significantly lower liver injury was found after transplantation of HOPE treated livers compared to nor-
mothermic perfusion, as shown by liver transaminases, measured in the recipient 24 h after DCD liver transplantation (n = 57) (a). Such findings were paralleled by higher cellular
energy after HOPE treatment, when compared to normothermic perfusion, measured through ATP content (n = 68) (b). The liver histology confirmed these findings with more
signs of injury after normothermic perfusion and transplantation, compared to HOPE (n = 6, duplicates of 2HPF per experiment per group) (c) (Mann-Whitney U-test was used for
statistical analysis).
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mitochondria are initial events during liver reperfusion, leading to a
multifactorial injury including mitochondrial ROS release, DAMP sig-
naling, and activation of non-parenchymal liver cells. Second, we
demonstrate that exposure of mitochondria to a combination of suc-
cinate and oxygen leads to significantly less mitochondrial FMN dis-
sociation under cold compared to normothermic conditions. Third,
we show, that hypothermic oxygenation of mitochondria induces a
metabolic reprogramming within one hour, with a significant
decrease of succinate and uploading of the intracellular nucleotide
content. Next, we translated our results to human and demonstrate
that FMN release and NADH oxidation during HOPE serves as an
easily detectable novel parameter to predict liver function prior to
implantation.
Our data underline recent findings that accumulation and mito-
chondrial oxidation of succinate causes extensive damage in trans-
planted organs, and should therefore primarily be targeted by new
therapeutic methods to improve outcome [23]. Mitochondrial com-
plex I catalyzes the first step of the mitochondrial electron transfer in
the respiratory chain. It contains 8 iron-sulfur clusters as well as non-
covalently bound FMN, and is solely responsible for the oxidation of
NADH, generated during catabolism (glycolysis, TCA cycle, etc.). It is
also the major contributor to ATP synthesis in mitochondria [12].
Under physiologic conditions, FMN is tightly bound to the enzyme.
However, FMN loss from complex I is possible when complex I is
fully reduced, i.e. when the electron transport chain is halted during
ischemia [15,16,24,25].
Recent reports have suggested, that mitochondrial RET can occur
between complex II and I early upon reperfusion of ischemic tissue,
due to ischemic accumulation of succinate [2628]. In addition, ade-
nine nucleotides are degraded during I/R, caused by progressive
hydrolysis of ATP to AMP during ischemia, with a further breakdown
by the purine nucleotide cycle [29,30], generating hypoxanthine and
inosine. During normothermic reperfusion, the restoration of adenine
nucleotide levels is delayed by approximately 45 min, due to the rela-
tively slow rate of the purine salvage pathway, resulting in low levels
of ADP during the early reperfusion phase [29,31,32]. Simultaneously,
accumulated succinate is rapidly oxidized by complex II under condi-
tions of ADP deficit, resulting in hyperpolarization of the membrane,
and therefore supporting RET at complex I [33]. In steady-state condi-
tions this leads to a complete reduction of the NAD+ pool and is also
associated with the highest rate of ROS formation in the mitochon-
drial matrix [11,33].
As demonstrated in brain mitochondria, an over-reduction of
complex I induce FMN dissociation from the enzyme, causing its
inactivation [14,15,24]. A similar loss of mitochondrial FMN during
ischemia has been described during cardiac I/R in a dog model
[25]. Here we confirm, that the presence of succinate triggers sig-
nificant mitochondrial FMN release and NADH accumulation in rat
and human DCD livers during normothermic oxygenated perfu-
sion, together with oxidative injury and downstream activation of
toll-like receptors of non-parenchymal liver cells. However, FMN
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Fig. 7. Human perfusate analysis during HOPE: Human livers donated after circulatory death (DCD), or donated after brain death (DBD), underwent hypothermic oxygenated perfu-
sion (HOPE) for 12h after cold storage prior to liver implantation. Perfusate fluorescence was measured during HOPE in 50 livers. Corresponding to experimental data in rodents,
human livers released FMN during HOPE (a). The amount of perfusate FMN within the first 30 min correlated well with graft outcome after transplantation, with a discriminative
threshold of 8 £ 103 arbitrary units of perfusate FMN fluorescence, e.g. 100 ng FMN/ml circulating perfusate = 0.2 mg FMN release/g liver (3l perfusate, 1.5 kg liver). Accordingly,
high FMN perfusate concentrations resulted in a very high percentage of graft loss after transplantation (6/9, 67%), in contrast to good outcome at low FMN perfusate values (1/41,
2.4 %) (a). FMN release during HOPE also discriminated highly between DCD and DBD livers (b), and FMN quantification at 30 min of hypothermic oxygenated perfusion revealed an
excellent c-statistic (0.9441) by ROC curve analysis (c). Mitochondrial metabolites were further quantified in the HOPE perfusate of human livers. The highest fold increase, compar-
ing lost vs survived grafts, was found for perfusate NAD and FMN (d). Predictive discrimination was achieved through either quantification of perfusate FMN within the first 30 min
(area under curve, AUC 1-30 min) or for single perfusate FMNmeasurements at 30 min (n = 50 human livers) (e). NADH quantification at 30 min of HOPE treatment in human livers
confirmed similar significant differences between lost and survived grafts after liver transplantation (7 grafts were lost, measurement done in triplicates) (f) (Mann-Whitney U-test
was used for statistical analysis). Perfusate levels of human DCD livers with high injury (graft loss) were in the range of rat livers perfusions with high doses of succinate, underlining
the clinical relevance of the model (g).
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appeared therefore not RET-induced. We interpreted this as direct
evidence for complex I damage with mitochondria operating pref-
erably in Mode 1 according to Murphy [1], underlining an early
oxidative injury of complex I, for example by modification of criti-
cal thiol residues (-SH) [34].
In contrast, oxygenation of liver tissue under hypothermic condi-
tions protected mitochondria strongly from FMN release, despite
excessive succinate load, while the addition of NADH donors pro-
voked FMN release also during hypothermic oxygenation. In addition,
the mitochondrial complex I and II activity even improved during 1 h
HOPE.
Such remarkable differences in FMN release under hypothermic
versus normothermic perfusion conditions is related to a unique
mitochondrial response under cold conditions. A slow-down of the
mitochondrial activity in the cold, e.g. by decreased proton motive
force during hypothermic oxygenation after ischemia, or by delayed
D-A transition of complex I may prevent over-reduction of FMN and
subsequently lessen FMNH2 release. Based on this, the central protec-
tive mechanism of cold oxygenation after ischemia depend on
effective oxidation of accumulated succinate while avoiding mito-
chondrial injury [35]. Likewise, protective effects of HOPE in rodent
DCD hearts were clearly related to succinate metabolization [36].
Of note, a reversible downregulation of the electron transport has
already been reported in all forms of mammalian hypometabolism
during natural hibernation [37,38], as well as after pharmacological
induced suspended animation [39]. We may speculate, that inducing
a hypometabolic state before normothermic reperfusion is eventually
related to an ancestral behavior of mitochondrial proteins in the cold,
similarly to the protection from oxidative stress during arousal after
torpor [38,40]. For example, arctic ground squirrels tolerate hypoxia
during arousal without subsequent development of relevant ische-
mia-reperfusion injury. Likewise, during hibernation, arterial oxygen
saturation is significantly higher compared to euthermia [41], and
the ATP level is well preserved [42], similarly to hypothermic oxy-
genated perfusion [30,4349]. These findings were paralleled by the
determination of the key role of complex I-derived oxidative stress in
aging comparing different species with a short or long life span.
A limitation of our model is the lack of a direct proof of FMN loss
by mitochondrial complex I. However, based on the comparison of
mitochondrial and perfusate FMN, which was inversely related, we
indirectly concluded mitochondrial origin of FMN release. Notably,
FMN sources in mammalian cells are limited, with only 6 out of 76
flavoproteins containing non-covalently bound FMN, which poten-
tially can be released. Of those, only NADH dehydrogenase, e.g. com-
plex I, is located intra-mitochondrial, thus underlining our
hypothesis.
Another shortcoming is the use of un-physiologic high succinate
concentrations in our perfusion model, e.g. 2.5, 25, 250 mM. How-
ever, perfusate succinate application was entirely pH-adjusted, and
was used as a tool to induce a highly standardized increased level of
mitochondrial succinate. Due to poor membrane permeability of suc-
cinate, the concentrations of perfusate succinate needed to be high
enough for provoking more than 10 fold changes in mitochondrial
succinate concentrations, which have been recently reported to occur
under liver ischemia [3].
We believe that our results have a direct clinical impact because
transferring organs into a hibernation-like status could be a novel
protective concept [34,40]. This approach is however in contrast to
an upfront normothermic liver perfusion strategy [5054]. Our data
demonstrate instead, that in situ and ex situ normothermic perfusion
is likely to induce inflammatory pathways through mitochondrial-
mediated injury, depending on the level of succinate accumulation,
consistent with recent findings on ex situ normothermic perfusion of
other solid organs, for example of ischemic hearts, lungs, and kidneys
[55]. This injury occurs within the first few minutes of normothermic
reperfusion and is unlikely to be completely preventable by inhibitors
of RET. Instead, an effective upregulation of mitochondrial repair
mechanism, as seen in vivo, would be required, implicating long-
term normothermic perfusion strategies, e.g. perfusion for several
days or weeks [56].
Importantly, mitochondrial injury can also occur during cold oxy-
genated perfusion, yet at much lower levels. The addition of mito-
chondria-targeted anti-oxidative scavengers to the machine
perfusate would, therefore, be a further topic of research [57]. The
unique figure of mitochondrial response at hypothermic tempera-
tures allows, however, fueling of accumulated succinate during cold
oxygenated perfusion, without significant injury to complex I. Simul-
taneously, the cellular ATP pool is uploaded by continuous fueling
proton pumps and ATP synthase. Liver cells are therefore recharged
with nucleotides without significant injury. Importantly, eventual
complex I injury, as displayed by FMN- and NADH release, during
hypothermic oxygenated perfusion can be quantified before using
the graft for transplantation. This measurement is elegantly per-
formed in a real-time fashion from perfusates obtained during
machine liver perfusion. Remarkably, such a concept originates from
an earlier publication 50 years ago on the fluorometric assessment of
mitochondrial redox changes [58].
In summary, we demonstrate, that perfusion of the ischemic liver
with a hypothermic oxygenated solution (HOPE) prevents the
impairment of the mitochondrial electron transport chain and pro-
tects from subsequent reperfusion injury. This result is in stark con-
trast to reperfusion under normothermic conditions. Short-term,
cold oxygenation for mitochondrial conditioning may, therefore, be
considered for ischemic solid human organs prior to ex situ normo-
thermic perfusion or implantation.
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